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Summary
In this work we have isolated a cDNA clone encoding the B cell antigen CD75. The amino
acid sequence of CD75 is shown to be identical to that of human cr2,6 sialyltransferase, believed
to be primarily associated with the Golgi complex. This is the first demonstration ofcell surface
expression of sialyltransferase which, in B cells, may play an important role in intercellular adhesion
and antigen presentation events.
C
D75 has recently been characterized as a B cell surface
molecule expressed predominantly on mature and acti-
vated B lymphocytes. The anti-CD75 mAb HH2 (1) has been
found to augment DNA synthesis in B cells stimulated by
anti-IgM antibodies. However, in some B cells lines, HH2
mAb produced an inhibitory effect upon DNA synthesis, sug-
gesting that CD75 may be involved in regulating B cell acti-
vation. In this work, we show that a cDNA clone encoding
CD75 is identical to a human sialyltransferase (2, 3) and 80%
homologous to the rat ot2,6 sialyltransferase (4). Sialyltrans-
ferases catalyze the attachment of sialic acids to the termini
ofoligosaccharides and are typically located in the Golgicom-
plex. Cell surface expression of a sialyl transferase in B cells
is particularly interesting in light of the observations that
sialation of cell surface oligosaccharides plays a role in reg-
ulating a variety of cellular functions including cell-cell in-
teraction (5), antigen presentation (6), and activation (7).
Materials and Methods
Isolation of the CD75 cDNA Clone.
￿
A cDNA library derived
from the Burkitt lymphoma Daudi cell line (8) was introduced
into COS cells by the DEAF-Dextran method (9, 10) and screened
with the HH2 mAb by successive rounds ofpanning and enrich-
ment as described (9, 10) .
Sequencing, RNA Hybridization.
￿
The CD75 cDNA clone was
subjected to digestion with several restriction endonucleases and
subdoned into Bluescript SK- and KS - vectors. Recombinant
clones were sequenced by the dideoxy method, modified to allow
the use offluorescein-labeled primers (11). Sequencing products were
analyzed by an automated sequencer (EMBL, Heidelberg, FRG)
(12, 13). T7 DNA polymerase, dNTPs, and ddNTPs were pur-
chased from Pharmacia-LKB (Bromma, Sweden).
Total cellular RNA was isolated by the LiCl/urea method (14),
loaded onto a 1% agarose gel, electrophoresed, transferred to nylon
membranes, and hybridized to "P-labeled CD75 cDNA as de-
scribed (15).
Results and Discussion
After three rounds ofselection,one of four randomly picked
colonies reacted with mAb HH2 by indirect immunofluores-
cence. The cDNA clone was reintroduced into COS cells and
found to react with all of the CD75 mAb (16) .
RNA blot analysis revealed a major 4.7-kb message ex-
pressed to a variable degree in three Burkitt lymphoma cell
lines Daudi, Raji, and Reh and very weakly in the T cell
leukemia Jurkat (Fig. 1). An identical message was expressed
in peripheral blood B cells, but only a very faintmessage was
observed in normal resting T cells (Fig. 1).
Nucleotide sequence analysis (Fig. 2) showed that the cDNA
insert consisted of 1,540 by with a single open reading frame
of 1,215 by encoding a 405 residue polypeptide with predicted
M, 46,367. The first ATG is embedded in an atypical initia-
tion codon sequence, although an A and a C are found at
positions -3 and -4 respectively, consistent with the con-
sensus initiationcodon sequence (17). Absence ofa consensus
leader peptide (18) suggests that the NH2-terminal domain
is intracellular. The first 9 residues are followed by a stretch
of 18 predominantly hydrophobic amino acidsconsistent with
a transmembrane domain. The extracellular domain is pre-
dicted to consist of 378 residues and contain two potential
Winked (Asn-Xaa-Ser/Thr, where Xaa cannot be a Pro)
glycosylation sites. Comparison with other known sequences
usingthe NBRF data base showed that the predicted peptide
sequence is identical to that encoded by cDNA clones spe-
cific for a human sialyltransferase (2,3 EMBL accession No.
X17247), with three exceptions: the substitution of a lysine
for a leucine residue at position 27; the substitution ofa threo-
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￿
RNA blot analysis of human B and T cells and cell lines
hybridized to CD75 cDNA probes . (Lane A) Burkitt lymphoma
Daudi; (lane B) Burkitt lymphoma Raji ; (lane C) Burkitt lymphoma
Reh ; (lane D) T cell leukemia Jurkat ; (lane E) normal resting T cells ;
(lane F) peripheral blood B cells .
nine for an arginine residue at position 73 ; and the absence
of a histidine residue at position 72 rendering the CD75 se-
quence one residue shorter than the predicted sialyltransferase
sequence (3) . Comparison ofCD75 with rat c12,6 sialyltrans-
ferase (4) showed80% homology. The region of greatest diver-
gence between rat and human sequences occurs between
residues 34 and 106, where the homology is only 50% . No
homologies with other known proteins were found .
Sialyl transferases belong to the broad family of glyco-
syltransferases, a group of integral membrane proteins of the
endoplasmic reticulum and Golgi apparatus involved in the
synthesis of glycoprotein and glycolipid sugar chains (19) .
Although all of the cloned glycosyltransferase genes encode
type II integral membrane proteins, the amino acid sequences
bear little homology to each other (19) . However, interspe-
cies homology for each enzyme is highly significant (19) .
(3-Galactoside a2,6 sialyltransferase, like other members
of the sialyltransferase family, catalyzes the transfer of sialic
acid to the terminal positions of the carbohydrate groups of
glycoproteins in the general reaction: CMP-SA + HO accep-
tor-CMP + SA-O-acceptor (4) . The principal localization
of sialyltransferases is believed to be the Golgi apparatus where
they participate in post-translational glycosylation pathways.
The present work suggests that an additional major site of
sialyltransferase expression, at least in B cells, is the cell sur-
face, whichmay have several important functional implications.
Sialic acid is an important constituent ofmany cell surface
proteins and is believed to help conceal surface structures in
certain circumstances (20) . In tumors, sialation of histocom-
patibility antigens may provide a shield against recognition
by cytolytic T cells (7, 21) . In physiologic situations, sialic
acid may regulate homotypic adhesion ofN-CAM (22) and
antigen presentation by accessory cells (6) .
B cells are highly motile and communicate with a variety
o£ other cell types as well as components of the extracellular
matrix. Activation induces modifications in the B cell pheno-
type, particularly with respect to cell surface expression of
molecules involved in cell-cell adhesion and antigen presen-
tation. By virtue of its capability to modify cell surface mol-
ecules, the sialyltransferase CD75 may play an important role
in several sectors ofB cell biology and provide a possible mech-






M I H T N L K K K F S C C V L V F L L F A V I C V W L E K K
361 AGAAAGGGAGTTACTATGATTCCTTTAAATTGCAAACCAAGGAATTCCAGGTGTTAAAGAGTCTGGGGAAATTGGCCATGGGGTCTGATTCCCAGTCTGTATCCTCAAGCAGCACCCAGG
31 K G S Y Y D S F K L Q T K E F Q V L K S L G K L A M G S D S Q S V S S S S T Q D
481 ACCCCACAGGCCGCCAGACCCTCGGCAGTCTCAGAGGCCTAGCCAAGGCCAAACCAGAGGCCTCCTTCCAGGTGTGGAACAAGGACAGCTCTTCCAAAAACCTTATCCCTAGGCTGCAAA
11 P T G R Q T L G S L R G L A K A K P E A S F Q V W N K D S S S K N L I P R L Q K
601 AGATCTGGAAGAATTACCTAAGCATGAACAAGTACAAAGTGTCCTACAAGGGGCCAGGACCAGGCATCAAGTTCAGTGCAGAGGCCCTGCGCTGCCACCCTCGGGACCATGTGAATGTAT
111 I W K N Y L S M N K Y K V S Y K G P G P G I K F S A E A L R C H L R D H V N V S
---CHO-
721 CCATGGTAGAGGTCACAGATTTTCCCTTCAATACCTCTGAATGGGAGGGTTATCTGCCCAAGGAGAGCATTAGGACCAAGGCTGGGCCTTGGGGCAGGTGTGCTGTTGTGTCGTCAGCGG





191 S L K S S Q L G R E I D D H D A V L R F N G A P T A N F Q Q D V G T K T T I R L
961 TGATGAACTCTCAGTTGGTTACCAGAGAGAAGCGCTTCCTCAAAGACAGTTTGTACAATGAAGGAATCCTAATTGTATGGGACCCATCTGTATACCACTCAGATATCCCAAAGTGGTACC
231 M N S Q L V T T E K R F L K D S L Y N E G I L I V W D P S V Y H S D I P K W Y Q
1081 AGAATCCGGATTATAATTTCTTTAACAACTACAAGACTTATCGTAAGCTGCACCCCAATCAGCCCTTTTACATCCTCAAGCCCCAGATGCCTTGGGAGCTATGGGACATTCTTCAAGAAA
271 N P D Y N F F N N Y K T Y R K L H P N Q P F Y I L K P Q M P W E L W D I L Q E I
1201 TCTCCCCAGAAGAGATTCAGCCAAACCCCCCATCCTCTGGGATGCTTGGTATCATCATCATGATGACGCTGTGTGACCAGGTGGATATTTATGAGTTCCTCCCATCCAAGCGCAAGACTG
311 S P E E I Q P N P P S S G M L G I I I M M T L C D Q V D I Y E F L P S K R K T D
1321 ACGTGTGCTACTACTACCAGAAGTTCTTCGATAGTGCCTGCACGATGGGTGCCTACCACCCGCTGCTCTATGAGAAGAATTTGGTGAAGCATCTCAACCAGGGCACAGATGAGGACATCT
351 V C Y Y Y Q K F F D S A C T M G A Y H P L L Y E K N L V K H L N Q G T D E D I Y
1441 ACCTGCTTGGAAAAGCCACACTGCCTGGCTTCCGGACCATTCACTGCTAAGCACAGGCTCCTCACTCTTCTCCATCAGGCATTAAATGAATGGTCTCTTG
391 L L G K A T L P G F R T I H C
Figure 2 .
￿
Nucleotide and deduced amino acid sequence of CD75. The predicted transmembrane domain is underscored . Potential sites of
Winked glycosylation are indicated -CHO- .
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